Eikon Therapeutics appoints new board director
Eikon Therapeutics, Inc. has appointed Ma.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company’s 2027 annual stockholder meeting, and will initially sit on the Board’s Compensation Committee.
Under the 2026 non-employee director compensation program, Ms. Francisco will receive an annual cash retainer of $50,000, paid quarterly, and an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. The option vests in 48 equal monthly installments, contingent on her continued Board service, and she has signed the company’s standard indemnification agreement.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Appointment approval date: June 5, 2026
Effective date: June 15, 2026
Annual director retainer: $50,000
+4 more
7 metrics
Appointment approval date
June 5, 2026
Board approved appointment of Ma. Fatima D. Francisco
Effective date
June 15, 2026
Effective date of Ms. Francisco’s Board service
Annual director retainer
$50,000
Cash retainer for Board service under 2026 program
Option shares granted
85,937 shares
Initial stock option award to Ms. Francisco
Option exercise price
$8.96 per share
Equal to closing price on grant date
Vesting schedule
48 monthly installments
Option vests monthly subject to continued Board service
Director class and term
Class I, until 2027 meeting
Serves until 2027 annual meeting or earlier departure
Key Terms
Class I director, Compensation Committee, non-employee director compensation program, indemnification agreement, +1 more
5 terms
Class I director regulatory
"appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026."
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Compensation Committee financial
"Ms. Francisco will initially serve on the Compensation Committee of the Board."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
non-employee director compensation program financial
"eligible to participate in the Company’s 2026 non-employee director compensation program, which provides for an annual retainer of $50,000"
indemnification agreement regulatory
"Ms. Francisco has also entered into the Company’s standard indemnification agreement for directors and officers."
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Item 404(a) of Regulation S-K regulatory
"there are no related person transactions within the meaning of Item 404(a) of Regulation S-K"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Eikon Therapeutics (EIKN) announce in this 8-K?
Eikon Therapeutics appointed Ma. Fatima D. Francisco as a Class I director, effective June 15, 2026. She will serve until the 2027 annual stockholder meeting and initially join the Board’s Compensation Committee, expanding the company’s board composition.
What compensation will Ma. Fatima D. Francisco receive as an EIKN director?
Ma. Fatima D. Francisco will receive a $50,000 annual cash retainer, paid in equal quarterly installments. The retainer is prorated based on days served each fiscal quarter under Eikon Therapeutics’ 2026 non-employee director compensation program.
What stock option grant did EIKN award to Ma. Fatima D. Francisco?
Eikon Therapeutics granted Ms. Francisco an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. The exercise price equals the closing price on the Nasdaq Global Select Market on the grant date.
How do Ma. Fatima D. Francisco’s EIKN options vest over time?
Her option to purchase 85,937 Eikon Therapeutics shares vests in 48 substantially equal monthly installments following the grant date. Vesting is conditioned on her continued service on the Board through each monthly vesting date.
What legal protection did Eikon Therapeutics provide its new director?
Ms. Francisco entered into Eikon Therapeutics’ standard indemnification agreement for directors and officers. Such agreements typically protect directors against certain liabilities arising from their service, subject to the terms and limitations described in the agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
